Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in what appears to be a recovery for startups trying to raise capital on the public market. Upstream Bio priced at $17 per share, the high end of the $15 to $17 range it set earlier this week. By selling 15 million shares — 2.5 million...

Sanofi is ending a Phase 2 clinical trial that’s testing a drug from Denali for multiple sclerosis, ending the development plan. Denali said in an SEC filing Thursday that Sanofi notified the company that the drug, oditrasertib, did not meet primary or key secondary endpoints in the study. The drug looked to block RIPK1, a signaling protein that when...

Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won over an FDA advisory committee on Thursday, likely setting up a tough decision for regulators in the coming months. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-6 that Stealth BioTherapeutics’ drug elamipretide...

The FDA has approved Roche’s inavolisib plus Pfizer’s Ibrance and fulvestrant in a subtype of breast cancer over a month before the target action date, the agency announced Thursday. The treatment, which will be marketed as Itovebi, is now approved for adults with endocrine-resistant, locally advanced or metastatic, PIK3CA-mutated HR-positive HER2-negative...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood cancer months or years after treatment, according to data published on Wednesday in the New England Journal of Medicine. Researchers have long known that therapies developed with lentiviral vectors could, in some cases, cause cancer,...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup to work on dual amylin calcitonin receptor agonists for obesity and other conditions. The world’s largest drugmaker by market capitalization will pay up to $1.4 billion to keep working with KeyBioscience on the potential new class...